

119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, 31-116, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16;

or variants and derivatives thereof; provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122, 24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, 31-122, or 32-122 of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof; and optionally further comprising an amino-terminal methionine.

Please amend the specification at page 14, line 1 to page 16, line 12 to read as follows:

As used herein, the term "truncated sTNFR(s)" includes one or more biologically active synthetic or recombinant molecules comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, 18-104, 18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2; and variants (including insertion, substitution and deletion variants) thereof (as described below); provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110,

3

McDonnell Buchman Hubert & Berghoff
100 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

4

McDonnell Buchman Hubert & Berghoff
100 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

portion thereof; and optionally further comprising an amino-terminal methionine.

Please amend the specification at page 17, line 18 to page 19, line 24 to read as follows:

In one basic embodiment, truncated sTNFRs of the present invention may be one or more polypeptides comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, 18-104, 18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2; or variants thereof, provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110, 12-110, 13-110, 14-110, 15-110, 16-110, 17-110, 18-110, or 19-110 of SEQ ID NO: 2, the polypeptide does not further comprise amino acid residues 111-161 of SEQ ID NO: 2, or a portion thereof.

In another basic embodiment, truncated sTNFRs of the present invention may be one or more polypeptides comprising amino acid residues 1-122, 1-121, 1-120, 1-119, 1-118, 1-117, 1-116, 1-115, 2-122, 2-121, 2-120, 2-119, 2-118, 2-117, 2-116, 2-115, 3-122, 3-121, 3-120, 3-119, 3-118, 3-117, 3-116, 3-115, 4-122, 4-121, 4-120, 4-119, 4-118, 4-117, 4-116, 4-115, 5-122, 5-121, 5-120, 5-119, 5-118, 5-117, 5-116, 5-115, 6-122, 6-121, 6-120, 6-119, 6-118, 6-117, 6-116, 6-115, 7-122, 7-121, 7-120, 7-119, 7-118, 7-117, 7-116, 7-115, 8-122, 8-121, 8-120, 8-119, 8-118, 8-117, 8-116, 8-115, 9-122, 9-121, 9-120, 9-119, 9-118, 9-117, 9-116, 9-115, 10-122, 10-121, 10-120, 10-119, 10-118, 10-117, 10-116, 10-115, 11-122, 11-121, 11-120, 11-119, 11-118, 11-117, 11-116, 11-115, 12-122, 12-121, 12-120, 12-119, 12-118, 12-117, 12-116, 12-115, 13-